131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes

Allogeneic hematopoietic cell transplant (HCT) is the only potentially curative therapy for relapsed or refractory (R/R) AML patients (pts). Due to high post-HCT relapse rates and high mortality, a minority of pts with TP53 mutations are offered HCT. Iomab-B (131I-apamistamab), an anti-CD45 radioimmunoconjugate, delivers high dose targeted radiation to hematopoietic cells, allowing for myeloablation and eradication of leukemic cells while also limiting off target toxicity. With better disease control and safer access to HCT, Iomab-B led induction/conditioning can potentially improve outcomes even in pts with TP53 mutation.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: James Foran, Boglarka Gyurkocza, Rajneesh Nath, Hannah Choe, Mark R. Litzow, Camille Abboud, Nebu Koshy, Patrick J. Stiff, Benjamin Tomlinson, Sunil H. Abhyankar, Sameem Abedin, George L Chen, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie J. Tags: 134 Source Type: research